| Product Name | MF | CAS | Details |
|---|
| Research Grade Sibrotuzumab (DHG32201) | Details |
| Research Grade Pembrolizumab (DHH02202) | Details |
| Research Grade Omalizumab (DHJ92701) | Details |
| Research Grade Dulaglutide (DHE40129) | Details |
| Research Grade Secukinumab (DHH28802) | Details |
| Research Grade Basiliximab (DHB95802) | Details |
| Research Grade Anti-Human TIE1 (DX-2240) (DHE13401) | Details |
| Research Grade Anti-Human CD340/ERBB2/HER2/NEU (AK-HER2) (DHC09625) | Details |
| Research Grade Anti-Human MDM2 (NMC-001) (DHF84502) | Details |
| Research Grade Runimotamab (DHC09612) | Details |
| Research Grade Tobemstomig (DHD30409) | Details |
| Research Grade Icrucumab (DHD27401) | Details |
| Research Grade Upifitamab (DHB65402) | Details |
| Research Grade Anselamimab (DHC65502) | Details |
| Research Grade Anti-Human CD221/IGF1R (BIIB022) (DHC29909) | Details |
| Research Grade Anti-Human HLA-G (TTX-080) (DHM00602) | Details |
| Research Grade Anti-Human CD47/MER6 (STI-6643) (DHG17623) | Details |
| Research Grade Tavolimab (DHE43203) | Details |
| Research Grade Anti-Human CD124/IL4R/IL-4Rα (BC 005) (DHD62608) | Details |
| Research Grade Lomtegovimab (DVV00313) | Details |
| Research Grade Anti-Human CD340/ERBB2/HER2/NEU (MI130004) (DHC09664) | Details |
| Research Grade Bepranemab (DHC82405) | Details |
| Research Grade Uliledlimab (DHD46602) | Details |
| Research Grade Zinlirvimab (DVV03103) | Details |
| Research Grade Becotatug (DHB86939) | Details |
| Research Grade Anti-Human CD20/MS4A1 (MT-3724) (DHC90736) | Details |
| Research Grade Vandortuzumab (DHJ76001) | Details |
| Anti-polyglutaminepolyQ Antibody (MW1) (RGK26001) | Details |
| Research Grade Ormutivimab (DVV03905) | Details |
| Research Grade Anti-Human CD340/ERBB2/HER2/NEU (FS102) (DHC09640) | Details |
| Research Grade Lorvotuzumab (DHC98501) | Details |
| Research Grade Pavurutamab (DHF92405) | Details |
| Research Grade Ivuxolimab (DHE43201) | Details |
| Research Grade Anti-Human IL13 (CNTO-5825) (DHE07712) | Details |
| Research Grade Davoceticept (DHJ70122) | Details |
| Research Grade Racotumomab (DGK11201) | Details |
| Research Grade Forimtamig (DHK07702) | Details |
| Research Grade Denecimig (DHB87902) | Details |
| Research Grade Visugromab (DHJ48302) | Details |
| Research Grade Dalotuzumab (DHC29901) | Details |
| Research Grade Garivulimab (DHJ70115) | Details |
| Research Grade Mupadolimab (DHD46604) | Details |
| Research Grade Anti-Human SIGLEC8/SAF-2 (AK001) (DHK16106) | Details |
| Research Grade Dalnicastobart (DHD68931) | Details |
| Research Grade Depemokimab (DHC13603) | Details |
| Research Grade Sibeprenlimab (DHB34101) | Details |
| Research Grade Tinurilimab (DHE25601) | Details |
| Research Grade Tuvonralimab (DHD17209) | Details |
| Research Grade Anti-SARS-CoV-2 NTD (CM25) (DVV00211) | Details |
| Research Grade Glenzocimab (DHJ60601) | Details |
| Research Grade Zeluvalimab (DHH02227) | Details |
| Research Grade Polatuzumab (DHE26301) | Details |
| Research Grade Revdofilimab (DHE43205) | Details |
| Research Grade Anti-Human MAPT/Tau/PHF-tau (E2814) (DHC82409) | Details |
| Research Grade Tepoditamab (DHJ95301) | Details |
| Research Grade Imsidolimab (DHJ72802) | Details |
| Research Grade Osemitamab (DHF19803) | Details |
| Research Grade Anti-Human CD112R/PVRIG (SRF813) (DHK16202) | Details |
| Research Grade Sasanlimab (DHH02219) | Details |
| Research Grade Libivirumab (DVV03003) | Details |
| Research Grade Gorivitug (DVV00342) | Details |
| Research Grade Anti-Human NGF/Beta-NGF (CRB0089) (DHB91709) | Details |
| Research Grade Toripalimab (DHH02208) | Details |
| Research Grade Nofazinlimab (DHH02230) | Details |
| Research Grade Narlumosbart (DHA30302) | Details |
| Research Grade Disitamab (DHC09603) | Details |
| Research Grade Pemtumomab (DHD14209) | Details |
| Research Grade Flanvotumab (DHD25201) | Details |
| Research Grade Belantamab (DHF92401) | Details |
| Research Grade Rolinsatamab (DHD18001) | Details |
| Research Grade Anti-Human CD274/PD-L1/B7-H1 (FAZ053) (DHJ70135) | Details |
| Research Grade Simaravibart (DVV00341) | Details |
| Research Grade Sevirumab (DVV05101) | Details |
| Research Grade Enlimomab (DHC16002) | Details |
| Research Grade Bremzalerbart (DZZ02003) | Details |
| Research Grade Derlotuximab (DHK10901) | Details |
| Research Grade Edobacomab (DXX02202) | Details |
| Research Grade Anti-RSV F/Fusion glycoprotein F0 (01.4B) (DVV02821) | Details |
| Research Grade Quavonlimab (DHD17206) | Details |
| Research Grade Lenzilumab (DHC06703) | Details |
| Research Grade Anti-Human ROR1 (ABL202) (DHF90702) | Details |
| Research Grade Tezepelumab (DHJ36101) | Details |
| Research Grade Vadastuximab (DHD37503) | Details |
| Research Grade Fletikumab (DHJ69101) | Details |
| Research Grade Anti-Human IL23A/IL-23p19 (QX 004N) (DHJ63111) | Details |
| Research Grade Tafasitamab (DHD10803) | Details |
| Research Grade Mosunetuzumab (DHC90716) | Details |
| Research Grade Landogrozumab (DHA30601) | Details |
| Research Grade Porgaviximab (DVV03604) | Details |
| Research Grade Prezalumab (DHB10201) | Details |
| Research Grade Adebrelimab (DHJ70108) | Details |
| Research Grade Nesvacumab (DHA42303) | Details |
| Research Grade Clazakizumab (DHC15805) | Details |
| Research Grade Anti-Human GPC3/Glypican 3 (CYT-303) (DHE84606) | Details |
| Research Grade Abituzumab (DHC21901) | Details |
| Research Grade Ranevetmab (DQB91702) | Details |
| Research Grade Inebilizumab (DHD10802) | Details |
| Research Grade Tiragolumab (DHH72401) | Details |
| Research Grade Anti-Human TSLP (HU23B12) (DHJ36103) | Details |
| Research Grade Enoblituzumab (DHJ04001) | Details |
| Product Total： Product Page： | ||||
| 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 | ||||